Navitoclax-piperazine

Cat. No.: HY-44432

CAS No.: 2143096-93-7

Molecular Formula: $C_{47}H_{56}ClF_3N_6O_5S_3$

Molecular Weight: 973.63

Target: Ligands for Target Protein for PROTAC; Bcl-2 Family

Pathway: PROTAC; Apoptosis

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (128.39 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.0271 mL	5.1354 mL	10.2708 mL
	5 mM	0.2054 mL	1.0271 mL	2.0542 mL
	10 mM	0.1027 mL	0.5135 mL	1.0271 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.08 mg/mL (2.14 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (2.14 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604)[1].

IC_{50} & Target

Bcl-xL

REFERENCES

[1]. Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA